Holen Sie sich die Stockscreener-App
0.0544
37.54%
-0.0327
Handel nachbörslich:
.05
-0.0044
-8.09%
Bio Path Holdings Inc Aktie (BPTH) Neueste Nachrichten
Antisense Oligonucleotide Therapeutics Clinical Trial - openPR.com
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path Holdings Q3 2025: Loss of $976K, Shares at $0.07News and Statistics - IndexBox
Bio-Path: Third Quarter Financial Highlights - Bitget
Bio-Path: Q3 Earnings Snapshot - Barchart.com
BPTH: Operational pause, depleted cash, and debt defaults highlight urgent need for new funding - TradingView — Track All Markets
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView — Track All Markets
North American Morning Briefing : Dow Futures Stall Ahead of Key Data -2- - marketscreener.com
Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - Sahm
Top News Today: Stocks Mixed as Energy Rises, Tech Falls - 富途牛牛
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
North American Morning Briefing : Stock Futures Rise as 2026 Trading Year Begins - MarketScreener
Mondego Bio selects ZE00-0388 as clinical candidate - BioWorld MedTech
What analyst consensus implies for Bio Path Holdings Inc. (IBP0) stockJuly 2025 Rallies & Daily Profit Focused Stock Screening - Улправда
Why analysts recommend Bio Path Holdings Inc. (IBP0) stock2025 Short Interest & Weekly Breakout Watchlists - Улправда
North American Morning Briefing : Dow Futures Climb, Nasdaq Futures Fall -2- - marketscreener.com
Armistice Capital LLC Trims Holdings in UiPath, Inc. $PATH - Defense World
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight - The Globe and Mail
Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
Critical Survey: NeuroBo Pharmaceuticals (NASDAQ:NRBO) versus Bio-Path (NASDAQ:BPTH) - Defense World
Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World
P 500 performance this yearInflation Watch & Technical Pattern Alert System - Newser
Can Bio Path Holdings Inc. (IBP0) stock retain market dominanceJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Acute Myeloid Leukemia Clinical Trial Pipeline Appears - GlobeNewswire
What consensus target says about Bio Path Holdings Inc. (IBP0) stockJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Analyzing Aadi Bioscience (NASDAQ:AADI) & Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path reports positive trial outcomes for cancer treatments - MSN
RNA Interference Pipeline Insights Report 2025: DelveInsight Highlights Emerging Therapeutics Transforming the Future Treatment Landscape - Barchart.com
Axos Financial loses $15M indemnification fight after merger trading fiasco - InvestmentNews
Bio-Path Holdings Inc. (BPTH) Stock Price | Live Quotes & Charts | PINL - StocksToTrade
MSN Money - MSN
North American Morning Briefing : Stock Futures Mostly Lower, AI Volatility Persists -2- - MarketScreener
Bio-Path Holdings Delays 10-Q Filing - MSN
Why ETFs are accumulating Bio Path Holdings Inc. (IBP0) stockTrade Volume Summary & Safe Entry Zone Tips - newser.com
Will Bio Path Holdings Inc. (IBP0) stock benefit from infrastructure billJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Is Bio Path Holdings Inc. (IBP0) stock a fit for income portfoliosTrade Performance Summary & AI Enhanced Trading Alerts - newser.com
Will Bio Path Holdings Inc. (IBP0) stock rise with strong economyRisk Management & Long Hold Capital Preservation Tips - newser.com
Bio-Path Holdings Seeks Financing for Strategic Turnaround - The Globe and Mail
4.73%
0.92%
Kapitalisierung:
|
Volumen (24h):